Hughes, Derralynn A <br/><br/>
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.  [electronic resource] 

 -  Journal of medical genetics  04 2017 
 - 288-296 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-6244 
<br/><br/><label>Standard No.: </label>10.1136/jmedgenet-2016-104178  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>1-Deoxynojirimycin--administration & dosage<br/>Administration, Oral<br/>Adolescent<br/>Adult<br/>Aged<br/>Enzyme Replacement Therapy--adverse effects<br/>Fabry Disease--drug therapy<br/>Female<br/>Humans<br/>Lysosomes--genetics<br/>Male<br/>Middle Aged<br/>Molecular Chaperones--administration & dosage<br/>Treatment Outcome<br/>alpha-Galactosidase--genetics